The vaccine method thus far has been a difficult p

The vaccine method thus far has been a difficult path to follow -- both because of many companies failing with their technology, and in a case like Dendreon (now owned by some other company) the price was so high, and manufacture so difficult because it was personalized for each patient, that insurance companies balked. (Insurance companies claimed that it wasn't more effective than current treatments -- which I think was NOT true -- but it hurt Dendreon.)

NWBO has had problems. Lots of problems. I lost money in NWBO. I sure hope that they are able to overcome the problems, that their "vaccine" technology works, and that they can bring the treatment to market. The more treatment options there are, the better.
But, they have a much tougher path ahead than IPIX will have with Brilacidin-OM and Bril-UP. The safety profile of Brilacidin thus far in these formulations has been incredibly good, and it is much easier and faster to measure results for an oral mucositis or an ulcerative proctitis/colitis/IBD application than it is for a cancer treatment.